Generic Versions of Semaglutide Disrupt India's Weight-Loss Drug Market
NEW DELHI: In a significant market shift, affordable generic versions of the popular weight-loss drugs Ozempic and Wegovy (semaglutide) have swiftly captured approximately 20% of India's nearly Rs 1,600 crore weight-loss market. This rapid penetration occurred within days of the drug's patent expiry on March 20, signaling a major transformation in the pharmaceutical landscape.
Early Movers Challenge Market Leader
A handful of early-moving pharmaceutical companies, including Torrent Pharmaceuticals, Sun Pharma, and Zydus Lifesciences, are already making substantial inroads into the market previously dominated by innovator firm Eli Lilly. Eli Lilly markets the competing weight-loss injection Mounjaro (tirzepatide), which has been the market leader in this segment.
Both semaglutide and tirzepatide belong to the GLP-1 (glucagon-like peptide-1) receptor agonists class of medications, which are primarily used for managing type 2 diabetes and obesity. These drugs work by mimicking the effects of natural hormones that regulate blood sugar and appetite.
Mounjaro's Market Position Under Pressure
Mounjaro, launched approximately a year ago, has dominated both the weight-loss and diabetes markets since October of last year, emerging as the largest-selling drug in the organized pharmaceutical retail market. It maintained this leading position in March as well, recording sales of Rs 114 crore.
However, the introduction of generic alternatives has created noticeable pressure on Mounjaro's market performance. According to the latest data from research firm Pharmarack, the launch of generics resulted in a Rs 21 crore month-on-month decline in Mounjaro's March sales. Simultaneously, the semaglutide market expanded by Rs 10 crore during the same period.
Pricing Strategy and Market Dynamics
Lower pricing strategies adopted by generic manufacturers and multinational corporation Novo Nordisk—which markets the original Ozempic and Wegovy—compared to tirzepatide's pricing, are strengthening semaglutide's competitive position. This observation comes from Sheetal Sapale, vice-president (commercial) at Pharmarack.
The market share data reveals significant changes in competitive dynamics. Eli Lilly has seen its market share decline to 56% in March from approximately 70% in October last year. In contrast, Novo Nordisk has demonstrated greater resilience against generic competition, retaining a 25% share in the GLP-1 segment despite the influx of new competitors.
Expanding Competitive Landscape
The market expansion has been substantial, with 26 brands launched by 13 different companies in March alone. Among generic manufacturers, several early entrants have secured considerable market share:
- Torrent Pharmaceuticals leads with an 8% market share
- Dr. Reddy's Laboratories follows closely
- Zydus Lifesciences maintains strong presence
- Lupin Limited shows competitive positioning
- Sun Pharma rounds out the major players
Torrent's higher market share can be attributed to its strategic offering of both oral and injectable formulations of semaglutide, providing patients and healthcare providers with more treatment options and flexibility. This dual-format approach appears to be resonating well in the market.
The rapid market penetration of generic semaglutide versions represents a significant development in India's pharmaceutical industry, potentially making weight-loss treatments more accessible to a broader population while intensifying competition among major drug manufacturers.
